Why Is BridgeBio Pharma, Inc. (BBIO) Among the Worst Performing Biotech Stocks in 2024?
J.P. Morgan Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Cuts Target Price to $40
Express News | BridgeBio Pharma Inc : JP Morgan Cuts Target Price to $40 From $43
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
Scotiabank Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $45
BridgeBio Pharma (BBIO) Gets a Buy From Scotiabank